// App-Quantinova.ai

: 10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK/06/016).

Researchers

Presenter

  • Isabel Syndikus

Principal Investigators

  • Clare Griffin

  • Lara Philipps

  • Alison Tree

  • Vincent Khoo

  • Alison Jane Birtle

  • Ananya Choudhury

  • Catherine Ferguson

  • Joe M. O'Sullivan

  • Miguel Panades

  • Yvonne L. Rimmer

  • Christopher D. Scrase

  • John Staffurth

  • Clare Cruickshank

  • Shama Hassan

  • Julia Pugh

  • David P. Dearnaley

  • Emma Hall

Medical Centers

  • Institute of Cancer Research Clinical Trials and Statistics Unit, Sutton, United Kingdom

  • Cambridge University Hospitals, Cambridge, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Rosemere Cancer Centre, Lancs Teaching Hospitals, & University of Manchester, University of Central Lancashire, Preston, United Kingdom

  • Queen's University Belfast, Belfast, United Kingdom

  • Clatterbridge Cancer Centre, Department of Radiotherapy, Liverpool, United Kingdom

  • Ipswich Hospital, Ipswich, United Kingdom

  • Sheffield Children's Hospital, Sheffield, United Kingdom

  • Velindre Hospital, Cardiff University, Cardiff, United Kingdom

  • Lincoln County Hospital, Lincoln, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved